ArticleCureus2026
Role of Apelin in Type II Diabetes Mellitus.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionDiabetes mellitus (DM) is characterised by persistent hyperglycaemia. It is associated with severe microvascular and macrovascular complications and leads to a significant decline in quality of life. Apelin is an endogenous ligand for the APJ receptor. There is some evidence in the literature that it promotes glucose uptake and improves insulin sensitivity and thus helps to control diabetes and prevent its complications in the initial stages. In later stages, however, apelin is found to aggravate the complications of diabetes by causing endothelial dysfunction and microangiopathic changes.
objectiveThe aim of our study was to assess apelin levels in patients with type II DM. Our primary objective was to find an association between serum apelin levels and insulin resistance. Secondary objectives were to find an association between serum apelin levels and the control and duration of diabetes, and also the micro- and macrovascular complications of type II DM. MATERIALS AND
methodsThe study was conducted among the Indian population in view of the massive prevalence of type II DM in India. A total of 60 patients were selected after applying the inclusion and exclusion criteria. A detailed history was taken for the duration and complications of diabetes, and samples were drawn for fasting and postprandial blood sugar levels, HbA1c, LFT (liver function test) and KFT (kidney function test), lipid profile, serum fasting insulin levels, and serum apelin levels. Urine albumin assessment by dipstick and UACR (urine albumin-creatinine ratio) and fundus examination were also done.
conclusionThe study found significantly high levels of serum apelin among the subjects. It also found significant associations between serum apelin levels and HOMA-IR (homeostatic model assessment for insulin resistance) and fasting blood sugar levels. Apelin levels were also found to be higher in patients with macro- and microvascular complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.